These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 16046101

  • 1. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR, Burgess DS.
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [Abstract] [Full Text] [Related]

  • 4. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
    Nicolau DP, Ambrose PG.
    Am J Med; 2001 Dec 17; 111 Suppl 9A():13S-18S; discussion 36S-38S. PubMed ID: 11755438
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
    Tasso L, de Andrade C, Dalla Costa T.
    Int J Antimicrob Agents; 2011 Oct 17; 38(4):307-13. PubMed ID: 21802907
    [Abstract] [Full Text] [Related]

  • 7. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
    Ambrose PG, Grasela DM.
    Diagn Microbiol Infect Dis; 2000 Nov 17; 38(3):151-7. PubMed ID: 11109013
    [Abstract] [Full Text] [Related]

  • 8. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
    Jones RN, Rubino CM, Bhavnani SM, Ambrose PG, Antimicrobial Resistance Rate Epidemiology Study Team Program.
    Antimicrob Agents Chemother; 2003 Jan 17; 47(1):292-6. PubMed ID: 12499204
    [Abstract] [Full Text] [Related]

  • 9. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.
    Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH.
    J Antimicrob Chemother; 2003 Sep 17; 52(3):435-40. PubMed ID: 12917247
    [Abstract] [Full Text] [Related]

  • 10. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS, Hall RG.
    Clin Ther; 2007 Jul 17; 29(7):1421-7. PubMed ID: 17825693
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR, Frei CR, Burgess DS.
    Clin Ther; 2004 Nov 17; 26(11):1800-7. PubMed ID: 15639692
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF.
    Antimicrob Agents Chemother; 2001 Oct 17; 45(10):2793-7. PubMed ID: 11557471
    [Abstract] [Full Text] [Related]

  • 13. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW.
    Antimicrob Agents Chemother; 2007 Apr 17; 51(4):1315-20. PubMed ID: 17296740
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I, Cars O.
    J Antimicrob Chemother; 2006 Nov 17; 58(5):960-5. PubMed ID: 16936293
    [Abstract] [Full Text] [Related]

  • 15. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
    Smith HJ, Noreddin AM, Siemens CG, Schurek KN, Greisman J, Hoban CJ, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2004 Sep 17; 48(9):3630-5. PubMed ID: 15328145
    [Abstract] [Full Text] [Related]

  • 16. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA, Ariano RE, Iacovides H, Sun S, Harding GK.
    J Antimicrob Chemother; 2003 Apr 17; 51(4):905-11. PubMed ID: 12654762
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ.
    J Chemother; 2002 Feb 17; 14 Suppl 2():13-21. PubMed ID: 12003136
    [Abstract] [Full Text] [Related]

  • 18. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R, Ramesh S, Bharathi MJ, Amuthan M, Viswanathan S.
    Indian J Pathol Microbiol; 2010 Feb 17; 53(2):276-80. PubMed ID: 20551532
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D, Zhong M, Mattoes H, Bui KQ, McNabb J, Nicolau DP, Quintiliani R, Nightingale CH.
    Antimicrob Agents Chemother; 2001 Mar 17; 45(3):794-9. PubMed ID: 11181363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.